Abstract: A left atrial appendage (LAA) occluder and an LAA occlusion system are disclosed. The LAA occluder enables an increased surgical success rate by allowing repeated good positioning, retrieval and release of the occluder and avoiding the problem of entanglement of the occluding stent during surgery. The LAA occluder includes an occluding stent, a proximal securing member a distal securing member. The occluding stent includes an occlusion structure and a traction structure. The delivery device includes a hollow push tube and a control shaft. The distal securing member can be driven by the control shaft to move toward the proximal securing member until a first distal end of the occlusion structure is in a collapsed configuration, where the distal securing member is blocked from further movement, avoiding the problem of entanglement arising from inward rolling of the occluding stent in the vent of human error.

Abstract: A left atrial appendage (LAA) closure (1) and a system (6) for delivering the LAA closure are disclosed. The LAA closure (1) includes supporting struts (11), wherein the supporting struts (11) are distributed peripherally around a first hub (10) and extend outward, the supporting strut (11) bifurcates at a first position (110) into a left branch (111) and a right branch (112). The left branch (111) of each supporting strut (11) and the right branch (112) of an adjacent supporting strut join each other at a second position (113) and extend distally to form a distal end. The LAA closure further includes a supporting rod (12) between adjacent supporting struts (11) which ensures stability, absence of irregular deformation and lateral slippage, of the LAA closure (1). With the supporting rods (12) between the adjacent supporting struts (11), the LAA closure (1) forms a dense mesh which imparts high overall strength of the LAA closure (1).

Abstract: A left atrial appendage (LAA) closure (1) and a system (6) for delivering the LAA closure are disclosed. The LAA closure (1) includes supporting struts (11), wherein the supporting struts (11) are distributed peripherally around a first hub (10) and extend outward, the supporting strut (11) bifurcates at a first position (110) into a left branch (111) and a right branch (112). The left branch (111) of each supporting strut (11) and the right branch (112) of an adjacent supporting strut join each other at a second position (113) and extend distally to form a distal end. The LAA closure further includes a supporting rod (12) between adjacent supporting struts (11) which ensures stability, absence of irregular deformation and lateral slippage, of the LAA closure (1). With the supporting rods (12) between the adjacent supporting struts (11), the LAA closure (1) forms a dense mesh which imparts high overall strength of the LAA closure (1).

Abstract: A left atrial appendage (LAA) closure (1) and a system (6) for delivering the LAA closure are disclosed. The LAA closure (1) includes supporting struts (11), wherein the supporting struts (11) are distributed peripherally around a first hub (10) and extend outward, the supporting strut (11) bifurcates at a first position (110) into a left branch (111) and a right branch (112). The left branch (111) of each supporting strut (11) and the right branch (112) of an adjacent supporting strut join each other at a second position (113) and extend distally to form a distal end. The LAA closure further includes a supporting rod (12) between adjacent supporting struts (11) which ensures stability, absence of irregular deformation and lateral slippage, of the LAA closure (1). With the supporting rods (12) between the adjacent supporting struts (11), the LAA closure (1) forms a dense mesh which imparts high overall strength of the LAA closure (1).

Abstract: Abuse-deterrent dosage forms (e.g., orally administered dosage forms, transdermal dosage forms, suppositories, etc.), processes for formulating pharmaceutical dosage forms comprising an active agent susceptible to abuse (e.g., an opioid agonist, a benzodiazepine, a stimulant) such that the resulting dosage forms are abuse-deterrent are described. Also described are methods of deterring abuse of pharmaceutical dosage forms.

Abstract: Abuse-deterrent dosage forms (e.g., orally administered dosage forms, transdermal dosage forms, suppositories, etc.), processes for formulating pharmaceutical dosage forms comprising an active agent susceptible to abuse (e.g., an opioid agonist, a benzodiazepine, a stimulant) such that the resulting dosage forms are abuse-deterrent are described. Also described are methods of deterring abuse of pharmaceutical dosage forms.

Abstract: Provided are particles comprising amphiphilic copolymers, having a crosslinked shell domain and an interior core domain. Also provided are compositions comprising such particles, including pharmaceutical compositions, methods of making the present particles, and methods of using such particles, for example for delivery of pharmaceutically active agents.